GlobeNewswire by notified

Basilea announces sale of preclinical oncology program to Nodus Oncology

Share
  • Sale of Basilea’s novel PARG inhibitor discovery program
  • Upfront and milestone payments of up to CHF 242 million and approximately 5% participation in net sales
  • Important step in implementing Basilea’s strategic refocus on anti-infectives

Basel/Allschwil, Switzerland, September 08, 2022

Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an asset purchase agreement with Nodus Oncology (“Nodus”) for Basilea’s novel poly(ADP-ribose) glycohydrolase (PARG) inhibitor discovery program. PARG is a key enzyme in the repair of DNA damage and essential for tumor cells to grow. Nodus is a UK-based company developing first and best-in-class molecules inhibiting novel DNA damage response (DDR) targets. It will partner with the Lead Discovery Center GmbH (LDC) in Germany to continue the development of this program.

Adesh Kaul, Chief Financial Officer of Basilea, said: “We are happy to have found a specialized oncology partner with significant expertise in the DNA damage response space. The structure of the transaction ensures that Basilea continues to participate in the long-term value creation potential of this exciting program. We also continue our ongoing partnering discussions for BAL0891 and our second pre-clinical program, for which we aim to complete transactions before the end of 2022.”

Ian Waddell, Chief Executive Officer of Nodus Oncology, said: “Nodus’ acquisition of Basilea’s PARG inhibitor program demonstrates our ongoing commitment to developing, and bringing to patients, drugs addressing next generation DDR targets. We are excited to expand our portfolio and we look forward to working with LDC to advance this program.”

Under the terms of the agreement, Basilea will receive upfront and near-term research milestone payments of CHF 1.0 million. Basilea is also eligible to receive further payments of up to CHF 241 million upon the achievement of predefined development, regulatory and sales milestones, in addition to receive approximately 5% of net sales.

In February this year Basilea announced its intention to focus on becoming a leading anti-infectives company and therefore to separate its oncology assets. Basilea has already made significant progress in the implementation of the new strategy and expects no material expenses related to oncology activities beyond 2022. Basilea is on track to achieve sustainable profitability from 2023.

About Nodus Oncology

Nodus Oncology is a biotech company developing first and best in class molecules focused on the DNA damage response (DDR) in patient sub-groups where molecular vulnerabilities exist. Founded by Cumulus Oncology, which contributes capital and oncology discovery and development expertise to the creation of new biotech companies, Nodus has received seed investment from both Cumulus Oncology and additional investors. Further information at: www.nodusoncology.com

About LDC

Lead Discovery Center GmbH (LDC) was established in 2008 by the technology transfer organization Max Planck Innovation, as a novel approach to capitalize on the potential of excellent basic research for the discovery of new therapies for diseases with high medical need. The LDC takes on promising early-stage projects from academia and transforms them into innovative pharmaceutical leads and antibodies that reach initial proof-of-concept in in vivo models as well as candidate nomination. In close collaboration with high-profile partners from research and industry, the LDC is building a strong and growing portfolio of small molecule and antibody leads with exceptional medical and commercial potential. The LDC sustains a long-term partnership with the Max Planck Society, KHAN-I GmbH & Co. KG and has formed alliances with AstraZeneca, Apeiron, Bayer, Boehringer Ingelheim, Merck KGaA, Daiichi Sankyo, Qurient, Jemincare, Novo Nordisk and Cumulus Oncology. In addition, LDC also works with leading translational drug discovery centers and with various investors to provide its assets for company creation. Further information at: www.lead-discovery.de.

About Basilea

Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. In addition, we have several preclinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

Peer Nils Schröder, PhD

Head of Corporate Communications & Investor Relations
Basilea Pharmaceutica International Ltd, Allschwil
Hegenheimermattweg 167b
4123 Allschwil
Switzerland
Phone+41 61 606 1102
E-mailmedia_relations@basilea.com
investor_relations@basilea.com

This press release can be downloaded from www.basilea.com.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Brookfield Reinsurance successfully completes Special Distribution10.12.2022 00:09:10 CET | Press release

BROOKFIELD, NEWS, Dec. 09, 2022 (GLOBE NEWSWIRE) -- Brookfield Reinsurance (NYSE, TSX: BAMR) (“Brookfield Reinsurance” or the “Company”) today announced that it has completed the previously announced special distribution (the “Special Distribution”) of shares of Brookfield Asset Management Ltd. (the “Manager shares”) to the holders of our Company’s class A exchangeable limited voting shares (“class A exchangeable shares”) and class B limited voting shares. The Special Distribution The Special Distribution was completed by way of a return of capital, resulting in a reduction to the par value of the class A exchangeable shares and class B limited voting shares of our Company in the amount of US$5.481 per share. The Name Change Brookfield Reinsurance also announced today that it has changed its name to “Brookfield Reinsurance Ltd.” It is expected that the Company’s class A exchangeable shares listed on each of the New York Stock Exchange and the Toronto Stock Exchange will begin trading u

Brookfield Corporation Successfully Completes Distribution of 25% Interest in its Asset Management Business10.12.2022 00:00:34 CET | Press release

BROOKFIELD, NEWS, Dec. 09, 2022 (GLOBE NEWSWIRE) -- Brookfield Corporation (NYSE: BN, TSX: BN) (the “Corporation”) and Brookfield Asset Management Ltd. (NYSE: BAM, TSX: BAM) (the “Manager”) today jointly announced the completion of the public listing and distribution of a 25% interest in the Corporation’s asset management business, through the Manager, by way of a plan of arrangement (“Arrangement”). The Corporation has changed its name from Brookfield Asset Management Inc. to Brookfield Corporation, with effect from today and at the open of markets on December 12, 2022, its shares will trade under the new ticker “BN” on both stock exchanges. The Manager takes the name Brookfield Asset Management Ltd. and has been successfully listed on the New York Stock Exchange and the Toronto Stock Exchange. At the open of markets on December 12, 2022, its shares will trade under the ticker “BAM” on both stock exchanges. Shareholders can now access a leading pure-play global alternative asset manag

Brookfield Announces Upgrade to Debt Rating9.12.2022 21:50:28 CET | Press release

BROOKFIELD, NEWS, Dec. 09, 2022 (GLOBE NEWSWIRE) -- Brookfield Asset Management Inc. (NYSE: BAM, TSX: BAM.A) (“Brookfield”) today announced that it has received an upgrade on its senior unsecured debt rating from Moody’s to A3 from Baa1, reflecting the strengthening and resiliency of the inflation-linked cash flows generated across Brookfield’s three core pillars – Asset Management, Insurance Solutions and its Operating Businesses. This rating will apply to Brookfield Corporation, which will be the new name of Brookfield Asset Management Inc., after the completion of the public listing and distribution of a 25% interest in Brookfield’s asset management business. Nicholas Goodman, Chief Financial Officer, stated, “We are pleased that the continued growth in our three core pillars, the stability and resiliency of the cash flows we generate, and our conservative capitalization is being recognized in the credit upgrade we received from Moody’s. This upgrade further reinforces the key diffe

Manager’s transactions9.12.2022 20:01:25 CET | Press release

December 9, 2022 – announcement no. 12 Shares received as a result of automatic reinvestment of dividends under short-term and long-term share-based incentive programs in Chr. Hansen Holding A/S administered by a third party. Please see attachment. For further information please contact: Anders Mohr Christensen, Vice President Group Strategy & Investor Relations, Tel: +45 2515 2364 Cristina Rønde Hefting, Senior Investor Relations Manager, Tel: +45 4072 1224 Kathrine Westermann, Head of Media Relations, Tel: +45 2381 5595 Attachment No. 12 Managers transactions

ING reports outcome of 2022 EU-wide Transparency Exercise9.12.2022 18:16:45 CET | Press release

ING reports outcome of 2022 EU-wide Transparency Exercise ING Groep N.V. notes the announcements made today by the European Banking Authority and the European Central Bank (ECB) regarding the information of the 2022 EU-wide Transparency Exercise and fulfilment of the EBA Board of Supervisors’ decision. The EBA Board of Supervisors approved the package for the EU‐wide Transparency Exercise, which since 2016 is performed on an annual basis and published along with the Risk Assessment Report (RAR). The annual transparency exercise will be based solely on COREP/FINREP data on the form and scope to assure a sufficient and appropriate level of information to market participants. The outcome of the exercise related to ING Group can be found in the annexes of the EBA website. The templates were centrally filled in by the EBA and sent afterwards for verification by banks and supervisors. Banks had the chance to correct any errors detected and to resubmit correct data through the regular supervi